Summary
Cannot evaluate alignment because no FDA-approved prescribing information (label text) for nivolumab (Opdivo) was provided. The submitted content appears to be a list of external claims (cost/coverage/timelines/programs/patents/supply) without any label text to verify against.
Category Scores
Accurate Statements
Unsupported Statements
Nivolumab (Opdivo) is a high-cost immunotherapy used for cancers like melanoma, lung cancer, and renal cell carcinoma.
No FDA label text was provided to verify the stated indication scope or characterization.
Without prior authorization or coverage determination, patients face out-of-pocket costs exceeding $10,000 per nivolumab infusion.
No FDA label text was provided regarding patient out-of-pocket costs or prior-authorization effects on cost.
U.S. patients without insurance approval wait 2-4 weeks longer on average for nivolumab initiation compared to those with seamless coverage.
No FDA label text was provided regarding coverage-related initiation delays.
Prior authorizations for nivolumab average 5-14 days through major U.S. payers like Medicare, UnitedHealthcare, or Blue Cross.
No FDA label text was provided regarding payer-specific prior authorization timing.
Delays in nivolumab prior authorization exceed 30 days in 20-30% of cases due to peer-to-peer reviews or appeals.
No FDA label text was provided regarding proportions of authorization delays or causes.
Medicare Part B covers nivolumab infusions in outpatient settings with processing often under 7 days.
No FDA label text was provided regarding Medicare Part B billing/processing timelines.
Commercial plans vary by formulary tier, and Tier 4 specialty drugs like nivolumab trigger stricter scrutiny.
No FDA label text was provided regarding formulary tiers or insurer scrutiny categories.
One analysis found that 15% of advanced NSCLC patients experienced tumor growth tied to coverage delays.
No FDA label text was provided regarding coverage delays and tumor growth linkage.
Bristol Myers Squibb patient support programs (e.g., Opdivo CoPay Support) can cover up to $25,000 annually for eligible commercially insured patients.
No FDA label text was provided regarding specific patient support program benefits/limits.
Eligibility for Opdivo co-pay support requires income verification and takes 1-3 days.
No FDA label text was provided regarding eligibility criteria or processing duration.
Uninsured patients qualify for free nivolumab via patient assistance.
No FDA label text was provided regarding patient assistance availability for uninsured patients.
Medicare approves nivolumab faster, with 90% within a week, under Part B for approved indications.
No FDA label text was provided regarding Medicare approval speed or percentages.
Under Medicare Part B, there is no prior authorization needed for on-label use post-NCCN guidelines.
No FDA label text was provided regarding prior authorization requirements or NCCN-guideline use.
Private insurers deny 10-15% of initial nivolumab requests.
No FDA label text was provided regarding insurer denial rates for nivolumab requests.
Private insurer denials often cite step therapy, such as requiring pembrolizumab first, and appeals extend timelines by 10-20 days.
No FDA label text was provided regarding step therapy requirements for nivolumab or appeal timeline extensions.
Medicaid varies by state, with some states mandating instant access for oncology emergencies.
No FDA label text was provided regarding Medicaid state policies or emergency access mandates.
BMS programs provide nivolumab free or low-cost for uninsured/low-income patients.
No FDA label text was provided regarding program pricing for uninsured/low-income patients.
BMS patient programs enabling treatment starts within days of application.
No FDA label text was provided regarding program turnaround times.
Independent foundations like CancerCare offer co-pay grants.
No FDA label text was provided regarding external foundation offerings.
Nivolumab faced U.S. supply constraints in 2023.
No FDA label text was provided regarding drug supply constraints.
Biosimilars for nivolumab are not available yet.
No FDA label text was provided to verify biosimilar availability status.
Opdivo's main patents are stated to expire 2028-2034.
No FDA label text was provided to verify patent expiration dates.
Oncologists submit prior authorizations day-of-diagnosis with detailed rationale (e.g., PD-L1 status and prior failures).
No FDA label text was provided regarding prior authorization submission practices or documentation specifics.
Using electronic portals like CoverMyMeds can provide 48-hour turnarounds in 70% of cases.
No FDA label text was provided regarding electronic portal turnaround times.
Appeal success rates for nivolumab denials are stated to exceed 80% when using NCCN compendium evidence.
No FDA label text was provided regarding appeal success rates or NCCN compendium evidence usage.
Contradictions
Important Omissions
FDA-approved prescribing information text for nivolumab (Opdivo), including sections relevant to the asked claims (Indications and Usage, Dosage and Administration, Contraindications, Warnings/Precautions, Adverse Reactions, Drug Interactions, and any relevant safety information).
Importance:
High
Safety Assessment
Potential Patient Risk:
High
The claims largely concern coverage, costs, timelines, and access, which cannot be validated against the FDA label because no label text was provided. Without on-label verification, accuracy and safety-relevance cannot be assessed.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Evaluated (Label Missing)
Primary Issue
No FDA prescribing information text was provided; therefore label alignment cannot be assessed.
Suggested Improvement
Provide the exact FDA label text sections to evaluate (at minimum: Indications and Usage, Dosage and Administration, Contraindications, Warnings and Precautions, Drug Interactions, Adverse Reactions, and Use in Specific Populations) and specify which of the provided claims are meant to be checked against those sections.